“Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial”, J of Skin, vol. 6, no. 6, p. s70, Nov. 2022, doi: 10.25251/skin.6.supp.70.